Current News
PRESS RELEASE
Accera, Inc. to Present at BIO CEO & Investor Conference
Broomfield, CO, February 7, 2008 – Accera, Inc. announced today that Dr. Steve Orndorff, Accera’s president and CEO, will be presenting at the BIO CEO & Investor Conference on February 12 at 3:30 p.m. EST at the Waldorf-Astoria in New York City.
Dr. Orndorff will provide an overview of Accera and its technology platform as well as a summary of the positive data from the company’s Phase IIb studies of its lead drug candidate, Ketasyn™ (AC-1202) in Alzheimer’s disease (AD) and age-associated memory impairment (AAMI). He will also discuss Accera’s plans to commercialize Ketasyn in the U.S. later this year as a prescription-only therapeutic product for the treatment of mild-to-moderate AD.
About Accera, Inc.
Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company’s lead candidate, Ketasyn™ (AC-1202), is a first-in-class molecule that has completed successful clinical trials for Alzheimer’s disease (AD) and age-associated memory impairment (AAMI). Accera plans to self-commercialize Ketasyn as a prescription-only therapeutic product for the treatment of AD in the US in 2008. A key element of Accera’s strategy is work with corporate partners to commercialize Ketasyn in non-U.S. markets, and to develop AC-1202 and other proprietary small molecule compounds in its pipeline for a range of neurodegenerative diseases. www.accerapharma.com
About Ketasyn™
Brain imaging techniques performed on Alzheimer’s patients reveal a dramatically decreased metabolism of glucose, the brain’s preferred source of energy. Known as neuronal hypometabolism, this condition resembles diabetes in the brain, or Type III diabetes. Ketasyn™ (AC-1202) is an orally available, liquid compound that is efficiently converted into ketone bodies, an alternative energy source that the brain can use even when glucose metabolism is impaired. By preserving glucose-deprived neurons, Ketasyn™ demonstrates neuroprotective and disease modifying potential in a number of neurodegenerative diseases characterized by neuronal hypometabolism.
Earlier this year, Accera completed two separate Phase II studies of Ketasyn in AD and age-associated memory impairment (AAMI). Ketasyn™ was shown to significantly improve memory and cognition using a battery of neuropsychometric tests, including ADAS-Cog, the FDA’s gold-standard efficacy measure for AD drugs. Ketasyn™ was also well tolerated in both indications, even when taken in addition to existing AD drugs, making it a promising candidate for a co-therapeutic approach to treating AD. This first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson’s disease, and selected orphan drug indications. Accera plans to commercialize Ketasyn™ as a prescription-only therapeutic product for the treatment of AD in 2008.
###